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agomelatine is a cost-effective treatment of major depressive disorders compared to 
generics of sertraline and venlafaxine.
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COST-UTILITY ANALYSIS (CUA) OF SERTINDOLE IN THE TREATMENT 
OF SCHIZOPHRENIA IN POLAND IN GENERAL POPULATION OF 
SCHIZOPHRENIC PATIENTS AND POPULATION OF PATIENTS 
INTOLERANT TO AT LEAST ONE OTHER ANTIPSYCHOTIC AGENT: A 
FIVE-YEAR MARKOV MODEL
Walczak J, Stelmachowski J, Obrzut G, Nogas G
Arcana Institute, Cracow, Poland
OBJECTIVES: To evaluate a cost-utility of sertindole compared with commonly used 
antipsychotic drugs in Poland: haloperidol and risperidone in the treatment of general 
population of schizophrenic patients and with risperidone in a group of patients 
intolerant to at least one other antipsychotic agent. METHODS: Cost-utility Markov 
model was constructed in ﬁ ve-year time horizon. Clinical effectiveness was assessed on 
the basis of RCTs, meta-analyses, observational studies and systematic reviews. The 
measures of effectiveness in the CUA were quality adjusted life-years (QALY) and life-
years gained (LYG). Direct medical costs were calculated from perspective of two payers 
(Polish National Health Fund and patient). Cost of: oral antipsychotic treatment, inpa-
tient care, primary health care, specialist care and adverse events treatment (extrapyra-
midal symptoms, sedation and weight gain) were included. Discount rates of 5% for 
costs and 3.5% for beneﬁ ts were used. Utilities and disutilities associated with AEs and 
relapse were derived from published literature. RESULTS: In general population of 
schizophrenic patients cost per QALY/LYG gained, using sertindole instead of risperi-
done is 97,396/26,585 PLN (c22,507/6,144) respectively; cost per QALY/LYG gained, 
using sertindole instead of haloperidol, is 82,132/20,670 PLN (c18,980/4,777) respec-
tively. In population intolerant to at least one other antipsychotic agent sertindole 
dominates risperidone (sertindole is less expensive and more effective considering both 
QALY/LYG gained). The sensitivity analysis indicated the robustness of the results. 
Obtained results are placed below the acceptability threshold (3xGDP per capita in 
Poland) which is about 105,500 PLN (c24,380). The 2009 weighted average exchange 
rate of Polish National Bank was c1 = PLN 4.3273. CONCLUSIONS: Treatment of 
schizophrenia with sertindole is a cost-effective strategy in comparison with risperi-
done and haloperidol therapy. In a group of patients intolerant to at least one other 
antipsychotic agent sertindole compared to risperidone is dominant strategy.
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OBJECTIVES: A recent meta-analysis has shown that escitalopram, a selective inhibi-
tor of serotonin reuptake, is one of the best choices when starting a treatment of 
moderate to severe major depressive disorder (MDD), with a favourable balance 
between efﬁ cacy and tolerability. Our objective was to perform an economic evalua-
tion of escitalopram versus citalopram in Israel. Citalopram is available as a generic 
drug and is included in the National Health Basket. METHODS: A decision tree model 
was used to assess the cost-utility of escitalopram versus citalopram in ﬁ rst-line treat-
ment of MDD. The model also accounted for second-, third- and fourth-line treat-
ments for patients not responding to therapy, with an overall time horizon of 12 
months. The analysis adopted a Health Maintenance Organization perspective. The 
main outcomes were quality-adjusted life-years (QALYs) and costs associated with 
local health care resource use (including drug use, and hospitalizations due to depres-
sion or suicide attempt). One-way and two-way sensitivity analyses were performed 
with the following parameters: probabilities of remission after initial and subsequent 
treatment, probabilities of relapse, suicide attempt and suicide-related death, number 
of hospitalization days due to a suicide attempt, costs of initial and subsequent treat-
ments and utility values. In addition, we used a Monte Carlo simulation. RESULTS: 
Compared to citalopram, escitalopram was more effective in terms of QALYs at a 
small incremental cost. The average QALYs of patients treated with escitalopram and 
citalopram were 0.728 and 0.720 respectively. The average cost of patients treated 
with escitalopram and citalopram were c105 and c63 respectively. The incremental 
cost-utility ratio was c5,150 (NIS23,875) per QALY. The variation of remission rates 
had the most inﬂ uence on this ratio in the sensitivity analyses. CONCLUSIONS: This 
local economic evaluation shows that compared to citalopram, escitalopram should 
be the preferred option in depression in Israel with an acceptable cost per QALY.
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OBJECTIVES: The main objective was to evaluate the consumption of antidepres-
sants, it s utilization as the basic aspect of the quality of life and to analyze the using 
of the original drugs or generics and to show the pharmacoeconomical impact of this 
group of drugs considering to it s ﬁ nancial costingness. METHODS: We used the 
analysis of consumption trend of antidepressants and the analysis of the trend of prices 
of antidepressants. We compared the original and generic market with antidepressants 
in Slovakia, we monitored and compared the prices for DDD and we evaluate the impact 
of new generics on the prices of originals as well. RESULTS: The consumption of 
antidepressants has increased because of increasing number depression illnesses which 
could be continually treated by modern antidepressants since successful treatment 
depends on relaps prevention. Such outcome could be reached by usage of the latest 
antidepressants with good compliance (escitalopram, venlafaxine, mirtazapin). Since 
2005 the consumption (packages sold) of antidepressant increased by 29% whereas 
the sales value stagnated as result of declining price. The price for daily recommended 
dosage decreased by 52.7% (from c0.80 in 2001 to c0.38 in 2008). This was inﬂ u-
enced mainly by the increasing number of generics medicaments which pushed the 
price down. In 2009 the price of original antidepressants fall by 26.4% as reason of 
generic molecules. Based on long-term surveys the similar trend could be expected also 
in the future. CONCLUSIONS: The utilization of antidepressants lead to better 
quality of life. From the pharmacoeconomical view, the development of new molecules 
goes hand in hand with the decrease of invalidation, decrease of the cost for hospi-
talization, as well as increase people ‘s ability to take care about themselves. On the 
other hand, the generic substitution leads to increase of the amount of treated patients.
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OBJECTIVES: Evaluate health care utilization among depressed patients before and 
after initiating duloxetine. METHODS: Depressed adults treated with duloxetine 
during January 1, 2006-September 30, 2007 were identiﬁ ed from the General Practice 
Research Database. All-cause health care utilization in the 12-months before and after 
treatment initiation was compared for patients and for the subset of patients with 
pre-period unexplained pain (UPain). Generalized Estimating Equation models were 
used to identify factors associated with the pre-post differences in hospitalization rates. 
Covariates included age, gender, pre-period comorbid conditions and medication use. 
RESULTS: A total of 909 patients were identiﬁ ed (mean age = 49.6; female = 67.7%), 
and 45% experienced UPain. Three-quarters of patients were prescribed a SSRI and 
11% were untreated with antidepressants before initiating duloxetine. Among 
patients, the rate of hospitalization was higher in the pre-period compared to the 
post-period (20.7% vs.16.5%, p = 0.006). There were no signiﬁ cant pre-post differ-
ences in the rates of accident & emergency visits, specialist referrals, or analgesic use. 
Among patients with UPain, fewer were hospitalized (26.2% vs. 19.1%, p = 0.003) 
or received analgesic in the post-period (77.0% vs. 71.7%, p = 0.015). Multivariate 
analysis conﬁ rmed fewer patients experienced hospitalization after duloxetine initia-
tion. All depressed patients with pre-period anxiolytic use (OR = 0.70, 95% CI, 
0.50–0.97, p = 0.033) or UPain patients with pre-period anticonvulsant use (OR = 
0.44, 95% CI, 0.21–0.91, p = 0.026) experienced a decreased hospitalization rate after 
initiating duloxetine and the magnitude of change was larger than that for patients 
not receiving these medications. All depressed patients with pre-period alcohol/drug 
dependence (OR = 1.83, 95% CI, 1.01–3.30, p = 0.045) and sleep disorder (OR = 
1.65, 95% CI, 1.05–2.59, p = 0.031) had an increase in the hospitalization rate from 
the pre- to post-period, while those without the conditions had a decreased hospitaliza-
tion rate. CONCLUSIONS: Hospitalization rates were lower following duloxetine 
initiation among depressed patients. Pre-period alcohol/drug dependence, sleep disor-
ders, anxiolytic and anticonvulsant use were associated with the pre-post difference 
in the hospitalization rate.
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OBJECTIVES: The lifetime emotional, social, and ﬁ nancial consequences experienced 
by individuals with schizophrenia spectrum disorders have signiﬁ cant effects on their 
families. Therefore, it is essential to increase the knowledge and awareness of the 
informal caregiver burden. Here, the purpose was to study objective burden (time and 
money spent), as well as subjective burden (care-related quality of life) of informal 
caregivers to patients with schizophrenia spectrum disorders. METHODS: Patients 
with schizophrenia spectrum disorders and their closest informal caregivers were 
recruited and patient- and caregiver-related characteristics and variables related to the 
provision of formal care were assessed. The subjective burden was assessed using the 
CarerQol. The objective burden was assessed prospectively during four weeks with 
daily recordings by the caregiver using diaries of the money and time spent on the 
patient. Data was analyzed using descriptive statistics. RESULTS: One-hundred and 
seven patients (53% females; mean age 43 ± 11 years) from nine centers in Sweden, 
and 118 of their closest informal care-givers (67% females; mean age 58 ± 15 years) 
entered the study. The mean (standard deviation, SD) GAF for the patients was 52 
(11). Subjective burden (CarerQol VAS) correlated positively to GAF. The mean (SD) 
time spent on caring for relatives with schizophrenia spectrum disorders was 22 (36) 
hours per week. Half of this (11 hours) was “stand-by” time and another 5 hours 
were spent on household work. Caregivers’ mean (SD) monthly expenses in support 
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of their relatives with schizophrenia were c292 (424), which corresponds to approxi-
mately 14% of the mean gross income of caregivers. Large expenditure items were 
groceries, clothes, rent and travel. CONCLUSIONS: The objective burden adds half-
time to an ordinary fulltime job (time spent on care) and additionally reduces gross 
incomes with approximately 14% (money spent on care) for informal caregivers to 
patients with schizophrenia spectrum disorders. 
MENTAL HEALTH – Patient-Reported Outcomes Studies
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OBJECTIVES: To examine risk of discontinuation of antipsychotics following dis-
charge from acute care settings in Florida for Medicaid-enrolled persons with schizo-
phrenia. METHODS: Medicaid claims, enrollment data, and community services data 
from the state mental health authority from 2004–2008 were used. Demographics, 
diagnosis, service history during the year before admission to acute care (hospitals and 
crisis units), and post-discharge psychopharmacologic treatment were obtained. 
Persons who received antipsychotic monotherapy and had a discharge diagnosis of 
schizophrenia were included. Cox proportional hazards regression estimated risk of 
post-discharge discontinuation of antipsychotics (formulary restrictions were not con-
sidered). Second-generation antipsychotics (SGAs) were examined individually; oral 
ﬁ rst-generation antipsychotics (FGAs) and depot FGAs were each considered as a 
group. Demographics, pre-admission service history, length of stay, and pre-discharge 
length of time receiving medication were control variables. Data were right-censored 
at end of Medicaid enrollment, end of data availability, or death. RESULTS: Partici-
pants (N = 6365) were 42.7 ± 11.2 (mean ± SD) years old; 61% male; 34% white. 
Mean ± SD length of acute care stay was 11.0 ± 19.7 days. Median length of time 
receiving medication post-discharge was 45 days. With risperidone long-acting therapy 
(RLAT) as reference, depot and oral FGAs had highest risk of discontinuation (hazard 
ratio [HR] = 2.49, P < .0001 and HR = 1.68, P = .0005), respectively. Risk was also 
elevated for oral SGAs aripiprazole (HR = 1.65, P = .0012), ziprasidone (HR = 1.46, 
P = .0191), olanzapine (HR = 1.43, P = .0202), and quetiapine (HR = 1.35, P = .0434), 
except for oral risperidone and clozapine. Fewer months receiving pre-discharge 
medication (HR = 1.04, P < .0001), black race (HR = 1.39, P < .0001), history of 
involuntary commitment (HR = 1.28, P < .0001), and more pre-admission acute care 
services (HR = 1.13, P = .0053) were associated with higher risk of discontinuation. 
CONCLUSIONS: Persons with schizophrenia taking oral and depot FGAs were at 
highest risk for discontinuation of medication after discharge from acute care. Those 
taking oral SGAs (except risperidone and clozapine) also may have higher risk of 
discontinuation than patients taking RLAT.
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PATIENTS WITH SCHIZOPHRENIA
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OBJECTIVES: Non-adherence to antipsychotic therapy can lead to increased risks of 
relapse and rehospitalization. Long-acting injectable antipsychotics have been shown 
to be effective and well-tolerated, with increasing evidence of a potential beneﬁ t on 
adherence. At the time of this study, only one long-acting injectable atypical antipsy-
chotic entity—risperidone—was approved for patients with a diagnosis of schizophre-
nia. The objective of this study was to determine the medication adherence rates of 
Medicaid patients treated with either 1) oral risperidone only, or 2) long-acting inject-
able risperidone +/− oral risperidone. METHODS: Texas Medicaid prescription claims 
data from January 2006 to December 2008 were analyzed for patients with schizo-
phrenia. Records were assessed for a period of 18 months (6-month pre-index period 
with no antipsychotics plus 12-month post-index period). a medication possession 
(MPR) ratio of ≥80% was considered adherent. RESULTS: A total of 1313 patients 
met inclusion criteria, and less than half, 48% (N = 626) had an MPR of at least 80%. 
Of the patients on long-acting injectables +/− oral risperidone, 60% (N = 96/160) were 
adherent with their regimen versus 46% (530/1153) for patients taking only oral 
risperidone. a logistic regression analysis adjusting for demographic covariates 
(gender, race, age) showed that patients on injectable +/− oral medications were about 
80 percent more likely to be adherent (OR = 1.82, 95% CI = 1.29–2.55; p = 0.0006) 
than patients on oral medication alone. There were no statistically signiﬁ cant differ-
ences in any of the demographic characteristics between the two groups. CONCLU-
SIONS: Overall, about half of the patients did not meet the deﬁ nition for medication 
adherence (MPR ≥ 80%) one-year after their index date. Long-acting injectable ris-
peridone had a higher rate of adherence compared to oral risperidone alone. With the 
release of newer atypical long-acting injections (paliperidone and olanzapine), future 
studies comparing adherence rates of these antipsychotic agents are needed.
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OBJECTIVES: Schizophrenia has been found to be associated with poor medication 
compliance, and a higher prevalence of diabetes. Once a hypoglycemic therapy is 
started, appropriate compliance to the therapy is crucial for good glycemic control. 
This study aimed to compare hypoglycemic therapy medication compliance, and 
health care costs after the initiation of the therapy, between type II diabetics with 
schizophrenia versus those without schizophrenia. METHODS: This study used the 
claims database of the National Health Insurance program. Enrollees who began oral 
hypoglycemic therapy in 2001–2002 (the index date), and had been diagnosed with 
schizophrenia and reﬁ lled at least one prescription of antipsychotic(s) in the year prior 
to the index date were included in the study (the case group). Enrollees without 
schizophrenia who began oral hypoglycemic therapy in 2001–2002 were selected from 
a randomly selected sample of the enrollees (the comparison group). Good medication 
compliance was deﬁ ned as an medication possession ratio (MPR) ≥ 0.8. Ordered 
logistic models were adopted to assess associations between factors with medication 
compliance. RESULTS: There were 1196 and 3188 subjects in the case group and 
comparison group, respectively. Forty-one percent of the case group and 30% of the 
comparison group were good compliant. The cost of hypoglycemic therapy was sig-
niﬁ cantly higher in the case group, while the total diabetes-related cost was not sig-
niﬁ cantly different between the two groups. The regression results indicated that 
comorbid schizophrenia was correlated with a higher likelihood of good compliance. 
In a subgroup analysis of diabetics with schizophrenia, good compliance to antipsy-
chotics in the previous year was signiﬁ cantly associated with a greater probability of 
being better compliant with hypoglycemic therapy. CONCLUSIONS: Diabetics with 
schizophrenia, compared with those without such a condition, were more compliant 
in their hypoglycemic therapy, and had higher cost of hypoglycemic therapy in the 
ﬁ rst year of the therapy.
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OBJECTIVES: According to evidence from scientiﬁ c literature the ease of administra-
tion, such as once-daily dosing, improves the adherence and persistance of patients 
with the pharmaceutical therapy. Adherence and persistance are key success factors 
in the treatment of schizophrenic patients, as drug discontinuation or non-adherence 
increase the risk of relapse, which eventually results in reduced quality adjusted life-
years and increased cost of care by more acute hospitalization episodes. Our objective 
was to analyze the impact of once-daily dosing vs. twice daily dosing on the discon-
tinuation rate of pharmaceutical therapy among patients with schizophrenia. 
METHODS: Our real world analysis is based on aggregated data from the Hungarian 
National Health Insurance Fund database. We selected adult patients (between 18–65 
years) on quetiapine therapy with F20 schizoprenia ICD-10 code between January and 
March 2008. We compared the one-year discontinuation rate among once-daily vs. 
twice daily quetiapine users. Discontinuation was deﬁ ned as no prescribed antipsy-
chotic medication in the N05A ATC group between May—July 2009. RESULTS: 
After 1 year 23.4% in the once-daily group compared to 27.2% in the twice-daily 
group discontinued the pharmaceutical therapy. Once-daily dosing reduced the rela-
tive risk of discontinuation by 13.9%. (χ2 test: p = 0,017). The absoluate risk reduction 
was 3.8% (NNT = 26.5). CONCLUSIONS: Our analysis indicates that once-daily 
dosing reduces the risk of drug discontinuation among schizophrenic patients. Short 
time-horizon, potential selection bias and confounding factors may limit the generaliz-
ability of our conclusions. Long-term observational study with multiple regression 
analysis based on anonimized individual patient records can conﬁ rm the validity of 
our ﬁ ndings.
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OBJECTIVES: Innovative antidepressants such as SSRIs and SNRIs have been widely 
adopted. However, the differences in patient antidepressant adherence and associated 
health care spending across patient factors and antidepressant choice needed further 
research. This study was trying to understand how patient factors and antidepressant 
choice inﬂ uenced medication adherence and associated health care expenditure. 
METHODS: A retrospective cross-sectional study was conducted using the 2000–
2007 Medical Expenditure Panel Survey (MEPS) database. a multiple OLS regression 
was used to examine MDD patient’s antidepressant adherence measured by propor-
tional days covered (PDC). a two-part model was implemented to study the impact 
of MDD patient factors and antidepressant choice on associated health care expendi-
ture. RESULTS: Linear regression models indicated that patient gender, ethnicity and 
